Ligand Pharma (LGND) Reports Encouraging Preclinical Data for LGD-6972 as Type 2 Diabetes Treatment
Tweet Send to a Friend
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) reports that a poster entitled “LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
